Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban
PG Tepper, J Mardekian, C Masseria, H Phatak… - PloS one, 2018 - journals.plos.org
Limited real-world data are available regarding the comparative safety of non-vitamin K
antagonist oral anticoagulants (NOACs). The objective of this retrospective claims …
antagonist oral anticoagulants (NOACs). The objective of this retrospective claims …
Major bleeding risk among non‐valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a “real‐world” observational study in the …
GYH Lip, X Pan, S Kamble, H Kawabata… - … journal of clinical …, 2016 - Wiley Online Library
Background Limited data are available about the real‐world safety of non‐vitamin K
antagonist oral anticoagulants (NOAC s). Objectives To compare the major bleeding risk …
antagonist oral anticoagulants (NOAC s). Objectives To compare the major bleeding risk …
Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin
GYH Lip, A Keshishian, S Kamble… - Thrombosis and …, 2016 - thieme-connect.com
In addition to warfarin, there are four non-vitamin K antagonist oral anticoagulants (NOACs)
available for stroke prevention in non valvular atrial fibrillation (NVAF). There are limited …
available for stroke prevention in non valvular atrial fibrillation (NVAF). There are limited …
Major bleeding risk during anticoagulation with warfarin, dabigatran, apixaban, or rivaroxaban in patients with nonvalvular atrial fibrillation
G Adeboyeje, G Sylwestrzak, JJ Barron, J White… - Journal of managed …, 2017 - jmcp.org
BACKGROUND: The use of non-vitamin K oral anticoagulants (NOACs) has increased
steadily following marketing approval; however, their relative safety in nonvalvular atrial …
steadily following marketing approval; however, their relative safety in nonvalvular atrial …
Effectiveness and safety of oral anticoagulants in non-valvular atrial fibrillation patients with prior bleeding events: a retrospective analysis of administrative claims …
GYH Lip, A Keshishian, A Kang, X Luo, N Atreja… - Journal of Thrombosis …, 2022 - Springer
Introduction There are a paucity of real-world data examining effectiveness and safety of non-
vitamin K antagonist oral anticoagulants (NOACs) and warfarin in nonvalvular atrial …
vitamin K antagonist oral anticoagulants (NOACs) and warfarin in nonvalvular atrial …
A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants
S Halvorsen, W Ghanima, I Fride Tvete… - European Heart …, 2017 - academic.oup.com
Aims We aimed to evaluate bleeding risk in clinical practice in patients with atrial fibrillation
(AF) being prescribed dabigatran, rivaroxaban, or apixaban compared with warfarin …
(AF) being prescribed dabigatran, rivaroxaban, or apixaban compared with warfarin …
Direct comparisons of effectiveness and safety of treatment with Apixaban, Dabigatran and Rivaroxaban in atrial fibrillation
M Jansson, S Själander, V Sjögren, H Renlund… - Thrombosis …, 2020 - Elsevier
Abstract Introduction Direct oral anticoagulants (DOACs) have been proven non-inferior or
superior to warfarin in preventing stroke and systemic embolism, with a lower risk of major …
superior to warfarin in preventing stroke and systemic embolism, with a lower risk of major …
Bleeding risk of apixaban, dabigatran, and low-dose rivaroxaban compared with warfarin in Japanese patients with non-valvular atrial fibrillation: a propensity …
S Kohsaka, T Murata, N Izumi, J Katada… - … medical research and …, 2017 - Taylor & Francis
Objectives: There is scarce evidence comparing novel oral anticoagulants (NOACs) with
warfarin in real-world settings in Japan. This study compared the risk of bleeding events …
warfarin in real-world settings in Japan. This study compared the risk of bleeding events …
Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study
LJ Kjerpeseth, R Selmer, I Ariansen, Ø Karlstad… - PLoS …, 2019 - journals.plos.org
Objective To compare effectiveness and safety of warfarin and the direct oral anticoagulants
(DOAC) dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation in routine …
(DOAC) dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation in routine …
Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation
NW Andersson, H Svanström, M Lund… - International Journal of …, 2018 - Elsevier
Background The comparative effectiveness and safety of individual direct oral
anticoagulants (DOACs) in clinical practice is largely unknown. The study objectives were to …
anticoagulants (DOACs) in clinical practice is largely unknown. The study objectives were to …